The Power of Real-World Data to Detect Adverse Events and Expedite FDA Postmarking Safety Commitments

Verana Ocular Email Header (1)-1

Access Your Copy of the White Paper

To overcome the limitations inherent in traditional clinical trials, researchers increasingly are turning to real-world data (RWD) to provide a picture of a drug’s efficacy and safety. One example is our work with Ocular Therapeutix to satisfy FDA postmarketing safety requirements.

This white paper includes:

  1. Why point-of-care EHR data is a game changer

  2. Details on the Ocular Therapeutix ReSure Sealant Study

  3. FDA and the use of real-world data

ocular_whitepaper
Dots Divider